Onconova Therapeutics Inc (NASDAQ:ONTX) has been given an average rating of “Hold” by the six brokerages that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $7.33.
Several research analysts have recently commented on the stock. HC Wainwright set a $6.00 target price on shares of Onconova Therapeutics and gave the stock a “buy” rating in a report on Thursday. Maxim Group reaffirmed a “buy” rating and set a $6.00 target price on shares of Onconova Therapeutics in a report on Thursday, November 2nd. Finally, Zacks Investment Research cut shares of Onconova Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, December 12th.
Onconova Therapeutics (NASDAQ:ONTX) opened at $1.69 on Friday. Onconova Therapeutics has a fifty-two week low of $1.21 and a fifty-two week high of $3.88. The company has a market cap of $18.20, a P/E ratio of -0.56 and a beta of 0.10.
A number of large investors have recently made changes to their positions in ONTX. Vanguard Group Inc. increased its stake in Onconova Therapeutics by 58.4% in the second quarter. Vanguard Group Inc. now owns 87,940 shares of the biopharmaceutical company’s stock valued at $190,000 after acquiring an additional 32,418 shares during the last quarter. Tyndall Capital Partners L P increased its stake in Onconova Therapeutics by 91.4% in the second quarter. Tyndall Capital Partners L P now owns 997,022 shares of the biopharmaceutical company’s stock valued at $2,154,000 after acquiring an additional 476,190 shares during the last quarter. Sabby Management LLC increased its stake in Onconova Therapeutics by 104.0% in the second quarter. Sabby Management LLC now owns 784,000 shares of the biopharmaceutical company’s stock valued at $1,693,000 after acquiring an additional 399,640 shares during the last quarter. Finally, 683 Capital Management LLC increased its stake in Onconova Therapeutics by 21.0% in the third quarter. 683 Capital Management LLC now owns 375,000 shares of the biopharmaceutical company’s stock valued at $641,000 after acquiring an additional 65,140 shares during the last quarter. 25.44% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Onconova Therapeutics Inc (ONTX) Receives Consensus Rating of “Hold” from Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/06/onconova-therapeutics-inc-ontx-receives-consensus-rating-of-hold-from-analysts.html.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.